Briefing
Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial
In this EBV DNA-integral randomized trial, adjuvant cisplatin-gemcitabine did not improve 5-year relapse-free survival versus observation among patients with detectable post-radiotherapy plasma EBV DNA (49.3% vs 54.7%; HR 1.09, P=0.75).
- Design: Evidence level 1
- Assay: Not named in the abstract